UCLA Hematology/Oncology - Santa Clarita

Valencia, California 91355

1 studies enrolling now · 8 studies all time

What they study most

Advanced Solid Tumors, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer, Breast Neoplasms, Cancer, Cancer of the Prostate, HER2 Positive Breast Cancer, HER2-positive Breast Cancer, Hormone Sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Prostate Cancer

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• Open-Label Extension and Safety Study of Talazoparib — Completed
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) — Completed
• A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors — Completed
• Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer — Completed